文献速递乳腺癌

胚系变异状态与高危早期乳腺癌治疗缓解的相关性:GeparOcto随机临床试验二次分析

Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer: A Secondary Analysis of the GeparOcto Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2020-01-01

该研究为GeparOcto随机临床试验的回顾性生物标志物二次分析,纳入914例高危早期乳腺癌患者,评估BRCA1/2及其他16个乳腺癌易感基因胚系变异与 nuevos 辅助化疗后病理完全缓解(pCR)的关系。结果显示BRCA1/2变异患者总体pCR率高于无变异者(60.4% vs 46.7%),非BRCA1/2易感基因变异与治疗反应无关;在三阴性乳腺癌亚组中,BRCA1/2变异者在PMCb臂和iddEPC臂均与较高pCR率相关。

要点

  • BRCA1/2胚系变异与高危早期乳腺癌新辅助化疗后更高pCR率相关。
  • 三阴性乳腺癌中BRCA1/2变异者在PMCb和iddEPC方案下pCR率均较高。
  • ERBB2阴性激素受体阳性乳腺癌中BRCA1/2变异亦与较高pCR率相关。

核心结论

  • BRCA1/2胚系变异与高危早期乳腺癌新辅助化疗后更高的pCR率相关,非BRCA1/2乳腺癌易感基因变异与治疗反应无关。
  • 在三阴性乳腺癌中,BRCA1/2变异者在PMCb和iddEPC方案下均观察到较高pCR率,提示iddEPC可能对BRCA1/2突变三阴性乳腺癌有效。
  • ERBB2阴性激素受体阳性乳腺癌中BRCA1/2变异与较高pCR率相关,提示治疗前应考虑胚系BRCA1/2检测。

研究设计与样本

  • 该研究为GeparOcto多中心前瞻性随机临床试验的回顾性生物标志物二次分析,2014年12月至2016年6月开展。
  • 对945例女性中的914例进行BRCA1/2及16个其他乳腺癌易感基因胚系变异分析,分析于2017年8月至2018年12月在德国科隆家族性乳腺癌和卵巢癌中心完成。
  • 主要结局为根据胚系变异状态的新辅助治疗后pCR比例(ypT0/is ypN0定义)。

主要发现

  • 914例不同乳腺癌亚型女性中,平均(范围)确诊年龄为48(21-76)岁。
  • 非BRCA1/2乳腺癌易感基因变异与治疗反应无关。

临床怎么用

  • 对高风险早期乳腺癌患者,尤其是三阴性或ERBB2阴性激素受体阳性亚型,治疗前应考虑胚系BRCA1/2检测以辅助治疗决策。
  • BRCA1/2突变三阴性乳腺癌患者除含铂方案外,iddEPC方案也可能有效,但需进一步前瞻性研究验证。

局限性

  • 该研究为回顾性二次分析,结果需前瞻性研究验证。
  • 研究仅纳入945例中的914例进行遗传分析,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The GeparOcto randomized clinical trial compared the efficacy of 2 neoadjuvant breast cancer (BC) treatment regimens: sequential intense dose-dense epirubicin, paclitaxel, and cyclophosphamide (iddEPC) vs weekly paclitaxel and nonpegylated liposomal doxorubicin (PM) in patients with different biological BC subtypes. Patients with triple-negative BC (TNBC) randomized to the PM arm received additional carboplatin (PMCb). Overall, no difference in pathologic complete response (pCR) rates was observed between study arms. It remained elusive whether the germline variant status of BRCA1/2 and further BC predisposition genes are associated with treatment outcome. OBJECTIVE: To determine treatment outcome for BC according to germline variant status. DESIGN, SETTING, AND PARTICIPANTS: This retrospective biomarker study is a secondary analysis of the GeparOcto multicenter prospective randomized clinical trial conducted between December 2014 and June 2016. Genetic analyses assessing for variants in BRCA1/2 and 16 other BC predisposition genes in 914 of 945 women were performed at the Center for Familial Breast and Ovarian Cancer, Cologne, Germany, from August 2017 through December 2018. MAIN OUTCOMES AND MEASURES: Proportion of patients who achieved pCR (ypT0/is ypN0 definition) after neoadjuvant treatment according to germline variant status. RESULTS: In the study sample of 914 women with different BC subtypes with a mean (range) age at BC diagnosis of 48 (21-76) years, overall higher pCR rates were observed in patients with BRCA1/2 variants than in patients without (60.4% vs 46.7%; odds ratio [OR], 1.74; 95% CI, 1.13-2.68; P = .01); variants in non-BRCA1/2 BC predisposition genes were not associated with therapy response. Patients with TNBC with BRCA1/2 variants achieved highest pCR rates. In the TNBC subgroup, a positive BRCA1/2 variant status was associated with therapy response in both the PMCb arm (74.3% vs 47.0% without BRCA1/2 variant; OR, 3.26; 95% CI, 1.44-7.39; P = .005) and the iddEPC arm (64.7% vs 45.0%; OR, 2.24; 95% CI, 1.04-4.84; P = .04). A positive BRCA1/2 variant status was also associated with elevated pCR rates in patients with ERBB2-negative, hormone receptor-positive BC (31.8% vs 11.9%; OR, 3.44; 95% CI, 1.22-9.72; P = .02). CONCLUSIONS AND RELEVANCE: Effective chemotherapy for BRCA1/2-mutated TNBC is commonly suggested to be platinum based. With a pCR rate of 64.7%, iddEPC may also be effective in these patients, though further prospective studies are needed. The elevated pCR rate in BRCA1/2-mutated ERBB2-negative, hormone receptor-positive BC suggests that germline BRCA1/2 testing should be considered prior to treatment start. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02125344.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Pohl-Rescigno E, Hauke J, Loibl S, et al. Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer: A Secondary Analysis of the GeparOcto Randomized Clinical Trial. JAMA Oncol. 2020. PMID: 32163106. doi:10.1001/jamaoncol.2020.0007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。